A Study to Assess the Adverse Events and How Bretisilocin Intramuscular Injection Moves Through the Body of Healthy Adult Participants

StatusCompleted
PhasePhase 1
SponsorAbbVie
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial completed
    • Primary and study completion dates changed from estimate of Sep 2026 to Sep 3, 2026
    • Eligibility criteria expanded, about 7 words
    • Site details revised
  2. Enrollment closed, study ongoing
    • Site details revised
    v3
  3. Recruitment opened
    • Study sites: 0 to 1
    v2
  4. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
AbbVie
349 trials monitored
See 27 trials at risk
This study will assess the adverse events, tolerability, and how bretisilocin intramuscular (IM) Injection moves through the body of healthy adult Japanese, Han Chinese, and Non-Asian volunteers participants.
Trial Details
NCT Number NCT07604558
Lead Sponsor AbbVie
Conditions
(from sponsor)		 Healthy Volunteer
Enrollment 26 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov